Eastwood Bio-Medical Canada Inc - Asset Resilience Ratio

Latest as of April 2016: 14.31%

Eastwood Bio-Medical Canada Inc (EBM) has an Asset Resilience Ratio of 14.31% as of April 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Eastwood Bio-Medical Canada Inc (EBM) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CA$506.76K

≈ $366.58K USD Cash + Short-term Investments

Total Assets

CA$3.54 Million

≈ $2.56 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2016)

This chart shows how Eastwood Bio-Medical Canada Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Eastwood Bio-Medical Canada Inc asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Eastwood Bio-Medical Canada Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Eastwood Bio-Medical Canada Inc for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$0.00	0%
Short-term Investments	CA$506.76K	14.31%
Total Liquid Assets	CA$506.76K	14.31%

Asset Resilience Insights

Moderate Liquidity: Eastwood Bio-Medical Canada Inc has 14.31% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Eastwood Bio-Medical Canada Inc Industry Peers by Asset Resilience Ratio

Compare Eastwood Bio-Medical Canada Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Eastwood Bio-Medical Canada Inc (2014–2016)

The table below shows the annual Asset Resilience Ratio data for Eastwood Bio-Medical Canada Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2016-10-31	0.00%	CA$0.00 ≈ $0.00	CA$3.24 Million ≈ $2.35 Million	--
2015-10-31	13.07%	CA$500.00K ≈ $361.69K	CA$3.82 Million ≈ $2.77 Million	-0.42pp
2014-10-31	13.49%	CA$550.00K ≈ $397.86K	CA$4.08 Million ≈ $2.95 Million	--

pp = percentage points

About Eastwood Bio-Medical Canada Inc

V:EBM Canada Biotechnology

Market Cap

$89.70 Million

CA$123.99 Million CAD

Market Cap Rank

#19687 Global

#664 in Canada

Share Price

CA$1.80

Change (1 day)

+0.00%

52-Week Range

CA$0.43 - CA$1.95

All Time High

CA$8.48